Aethlon’s Blood Filter Reveals a New Target in the Fight Against Long COVID

SAN DIEGO, CA – June 26, 2026 – For the millions grappling with the debilitating and often mysterious symptoms of Long COVID, any glimmer of scientific clarity is a significant event. Today, San Diego-based Aethlon Medical delivered just that, announcing peer-reviewed research that identifies a novel biomarker in the blood of Long COVID patients and, more importantly, a potential way to remove it.

The study, published in the International Journal of Molecular Sciences, provides a crucial piece of the puzzle for a condition that has largely evaded a clear biological definition. It suggests that the lingering illness may be driven, at least in part, by tiny biological packages called extracellular vesicles (EVs), and that Aethlon’s blood-purifying device, the Hemopurifier®, could be a tool to fight back.

A New Target for a Mysterious Ailment

At the heart of the discovery are extracellular vesicles—sub-cellular particles that act as messengers, carrying proteins and genetic material between cells. While essential for normal biological function, they can also spread disease. The new research, conducted with the University of California, San Francisco (UCSF) using samples from its long-term COVID study (LIINC), found that patients with Long COVID had roughly double the amount of a specific type of EV compared to individuals who had fully recovered.

These particular EVs are coated with a sugar called mannose. The study demonstrated that Aethlon's proprietary GNA affinity resin—a substance derived from the snowdrop plant lectin and the active component in its Hemopurifier—effectively binds to and captures these mannose-coated vesicles. By removing these particles from blood plasma, the treatment also significantly reduced seven types of circulating microRNAs linked to inflammation and immune dysregulation. This finding establishes a direct mechanistic link between the company's technology and a potential driver of Long COVID pathology.

This isn't the first time researchers have implicated EVs in Long COVID. Other studies have found viral fragments hiding inside these vesicles long after the initial infection has cleared, suggesting they may act as persistent reservoirs that continually provoke the immune system. Aethlon's research, however, is among the first to not only identify a specific type of EV as a biomarker but also demonstrate a targeted method for its removal.

The Hemopurifier: A 'Pipeline in a Single Device'?

The Hemopurifier operates much like a dialysis machine, filtering a patient's blood outside the body. But instead of just removing metabolic waste, its specialized cartridge is designed to capture specific microscopic threats. This versatility is central to Aethlon's strategy. The device already holds two FDA "Breakthrough Device" designations—one for treating advanced cancers where EVs are known to fuel tumor growth and immune evasion, and another for life-threatening viruses that have no other treatment options.

While the Long COVID findings are a major development, Aethlon’s leadership is managing expectations. "The publication of this study contributes to the scientific understanding of the biological mechanisms underlying Long COVID while strengthening the rationale for evaluating the Hemopurifier in this significant area of unmet medical need," said Jim Frakes, Aethlon's CEO and CFO. He was quick to add, "While the Company's current resources and primary focus remain dedicated to advancing our Australian oncology clinical trial, these findings provide additional translational evidence supporting future preclinical and clinical studies."

This careful positioning highlights the core challenge for a clinical-stage company: balancing promising new avenues with the immense cost of late-stage trials. Aethlon is currently focused on its oncology study in Australia, which is evaluating the Hemopurifier in combination with checkpoint inhibitor therapies for solid tumors. Yet, Frakes's vision for the device is expansive. "We believe there exists a 'pipeline within a single device,'" he noted, reinforcing the idea that the Hemopurifier is a platform technology with the potential to address a host of diseases driven by circulating pathogens and pathological EVs.

Navigating the Long COVID Therapeutic Maze

The need for an effective Long COVID treatment is staggering. An estimated 20-25 million people in the U.S. alone suffer from the condition, which can manifest as brain fog, chronic fatigue, cardiovascular issues, and a host of other persistent symptoms. The therapeutic landscape is a frustrating mix of symptom management and repurposed drugs, with no single treatment proving broadly effective in rigorous trials. The global market for Long COVID therapeutics, currently valued at over $3 billion, is projected to surge past $17 billion by 2033, a testament to the immense unmet need.

Within this landscape, the concept of blood purification, or therapeutic apheresis, is gaining traction. Small studies have suggested that filtering the blood can alleviate some Long COVID symptoms, possibly by removing inflammatory factors or microclots. Aethlon's approach is a more targeted version of this concept, aiming to remove a specific, identified culprit rather than performing a general cleaning. If proven effective in clinical trials, it could represent a significant leap forward from supportive care to a direct therapeutic intervention.

The Road Ahead: Balancing Promise with Pragmatism

For Aethlon Medical, this scientific validation is a crucial step, but the path to commercialization is long and fraught with financial hurdles. As a clinical-stage company, Aethlon currently generates no revenue and, according to its recent SEC filings, faces a "going-concern qualification," signaling substantial doubt about its ability to fund operations for the next year without raising additional capital. The company had approximately $5.5 million in cash as of March 31, 2026.

To bridge this gap, Aethlon is actively seeking funding, recently filing for a stock and warrant offering to raise up to $12 million. While necessary for survival and progress, such moves inevitably lead to the dilution of existing shareholders' equity—a classic biotech dilemma. The promise of a new application in the massive Long COVID market is a powerful narrative for attracting new investment, but it remains a future prospect. The company's immediate fate hinges on the results of its Australian oncology trial and its ability to keep the lights on. This new research adds a compelling chapter to Aethlon's story, but the most critical parts are yet to be written.